CSL – Macquarie rates the stock as Outperform

By Broker News | More Articles by Broker News

US flu dose distributions and early-season vaccination rates are up 10% and 6% respectively for the 2018-19 season. Macquarie expects a positive mix shift which will support the near-term outlook for Seqirus.

Moreover, a pipeline of late-stage products are in development and there are additional growth avenues over the medium to longer term. Outperform rating maintained. Target is $230.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.

Target price is $230.00.Current Price is $190.95. Difference: $39.05 – (brackets indicate current price is over target). If CSL meets the Macquarie target it will return approximately 17% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →